{
  "paper_id": "d6a325260dac29bfe718f1e57160583cb23b5908",
  "metadata": {
    "title": "The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin",
    "coda_data_split": "train",
    "coda_paper_id": 10657,
    "coda_has_expert_labels": false,
    "subset": "comm_use_subset"
  },
  "abstract": [
    {
      "original_text": "Emerging evidence suggests that dipeptidyl peptidase-4 (DPP-4) inhibitors used to treat type 2 diabetes may have nephroprotective effects beyond the reduced renal risk conferred by glycemic control. DPP-4 is a ubiquitous protein with exopeptidase activity that exists in cell membrane-bound and soluble forms.",
      "sentences": [
        [
          {
            "segment_text": "Emerging evidence suggests that dipeptidyl peptidase-4 ( DPP-4 ) inhibitors used to treat type 2 diabetes may have nephroprotective effects beyond the reduced renal risk conferred by glycemic control .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "DPP-4 is a ubiquitous protein with exopeptidase activity that exists in cell membrane-bound and soluble forms .",
            "crowd_label": "background"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "1",
    "sentence_num": "2",
    "segment_num": "2",
    "token_num": "47"
  }
}